Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost

2017 ◽  
Vol 122 (6) ◽  
pp. 464-471 ◽  
Author(s):  
Alba Fiorentino ◽  
Rosario Mazzola ◽  
Stefania Naccarato ◽  
Niccolò Giaj-Levra ◽  
Sergio Fersino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Volumetric Modulated Arc Therapy ◽  
Bilateral Breast Cancer ◽  
Simultaneous Integrated Boost ◽  
Synchronous Bilateral Breast Cancer ◽  
Arc Therapy ◽  
Integrated Boost ◽  
Cancer Irradiation

scholarly journals First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer

2017 ◽  
Vol 90 (1077) ◽  
pp. 20170152 ◽  
Author(s):  
Tabassum Wadasadawala ◽  
Shanu Jain ◽  
Siji Paul ◽  
Reena Phurailatpam ◽  
Kishore Joshi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Helical Tomotherapy ◽  
Bilateral Breast Cancer ◽  
Simultaneous Integrated Boost ◽  
Clinical Report ◽  
Synchronous Bilateral Breast Cancer ◽  
Integrated Boost

scholarly journals Treatment planning comparison of volumetric modulated arc therapy with Trilogy and Halcyon for bilateral breast cancer

2021 ◽  
Author(s):  
Tao Sun ◽  
Xiutong Lin ◽  
Guifang Zhang ◽  
Qingtao Qiu ◽  
Chengqiang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Bilateral Breast Cancer ◽  
Planning System ◽  
Skin Dose ◽  
Delivery Time ◽  
Dose Volume ◽  
Arc Therapy ◽  
The Mean

Abstract Background: The Halcyon is a new machine from the Varian company. The purpose of this study was to evaluate the dosimetry of the Halcyon in treatment of bilateral breast cancer with volumetric modulated arc therapy. Methods: On CT images of 10 patients with bilateral breast cancer, four Halcyon plans with different setup fields were generated, and dosimetric comparisons using Bonferroni’s multiple comparisons test were conducted among the four plans. Whole and partial arc plans on the Trilogy and the Halcyon, referred to as T-4arc, T-8arc, H-4arc and H-8arc, were designed. The prescription dose was 50 Gy in 2-Gy fractions. All plans were designed with the Eclipse version 15.5 treatment planning system. The dosimetric differences between whole and partial arc plans in the same accelerator were compared using the Mann-Whitney U test. The better Halcyon plan was selected for the further dosimetric comparison of the plan quality and delivery efficiency between the Trilogy and the Halcyon. Results:Halcyon plans with high‐quality megavoltage cone beam CT setup fields increased the Dmean, D2 and V107 of the planning target volume (PTV) and the V5 and Dmean of the heart, left ventricle (LV) and lungs compared with other Halcyon setup plans. The mean dose and low dose volume of the heart, lungs and liver were significantly decreased in T-8arc plans compared to T-4arc plans. In terms of the V5, V20, V30, V40 and Dmean of the heart, the V20, V30, V40 and Dmean of the LV, the V30, V40, Dmax and Dmean of the left anterior descending artery (LAD), and the V5 and V40 of lungs, H-8arc was significantly higher than H-4arc (p<0.05). Compared with the Trilogy’s plans, the Halcyon’s plans reduced the high-dose volume of the heart and LV but increased the mean dose of the heart. For the dose of the LAD and the V20 and V30 of lungs, there was no significant difference between the two accelerators. Compared with the Trilogy, plans on the Halcyon significantly increased the skin dose but also significantly reduced the delivery time. Conclusion: For the Halcyon, the whole-arc plans have more dosimetric advantages than partial-arc plans in bilateral breast cancer radiotherapy. Although the mean dose of the heart and the skin dose are increased, the doses of the cardiac substructure and other OARs are comparable to the Trilogy, and the delivery time is significantly reduced.

Sign in / Sign up

Export Citation Format

Share Document